At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 89 enrolled
Drug / intervention
1 +1 moredrug
Likely dose
2 180mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.
In Brief
A Phase 4 clinical trial evaluating 1 and 2 for Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft. Completed, enrolled 89 participants across 19 sites.
Detailed Summary
Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2010
Enrollment StartMay 2010
Primary CompletionApr 2013
TodayJul 2026
First PostedJan 26, 2010
Enrollment StartMay 1, 2010
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.4 years ago
Interventions
1drug
Continue with same dose of MMF as patient was taking before randomisation
2drug
Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours